Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Guy's and St Thomas' NHS Foundation Trust | OTHER |
| University of Nottingham | OTHER |
| University of Sheffield | OTHER |
| Imperial College London |
Not provided
Not provided
Not provided
Not provided
An outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study
A 6-month parallel group assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of eczema in neonates, with an embedded mechanistic study.
The overall rationale is that by installing a domestic water softener around the time of birth, the infant will be exposed to softened water rather than hard water for bathing and that this will be less irritating to the skin than hard water and so associated with a lower risk of eczema development. The primary objective is to determine the feasibility of conducting a subsequent definitive RCT that will investigate whether installation of a domestic water softener around the time of birth can prevent eczema in high-risk babies. The secondary objective is to explore the likely mechanisms by which water softeners might prevent eczema.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Domestic ion-exchange water softener | Experimental | The intervention group will have a domestic ion-exchange water softener installed prior to birth. |
|
| Usual hard water supply | No Intervention | The control group will receive their usual domestic water supply. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Domestic ion-exchange water softener | Device | Ion-exchange water softeners exchange calcium and magnesium, amongst other divalent cations, for monovalent sodium cations using a polystyrene resin. The sodium ions come from sodium chloride (common salt). The salt needs to be topped up every 3-4 weeks and sufficient quantities of block salt will be supplied to participants. The water softener used in this study does not require electricity and has two cylinders of resin which are used alternately. A control valve alternates the flow between the two cylinders and ensures a constant supply of regenerated resin. Ion-exchange water softeners typically reduce downstream water hardness to close to zero. |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of eligible families screened who are willing and able to be randomised. | This is key to the determination of the likely success of a future, large-scale definitive randomised controlled trial (RCT). | Before birth |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of pregnant women approached who agree to be screened | Before birth | |
| Proportion of families eligible on screening that cannot have a water softener installed (e.g. due to landlord or local authority refusal, technical (plumbing) reasons) | Before birth |
| Measure | Description | Time Frame |
|---|---|---|
| Transepidermal water loss (TEWL) | at birth, 4 weeks, 3 & 6 months oif age | |
| Cutaneous cytokine profiles | e.g. interleukin-1 levels | at birth, 4 weeks, 3 & 6 months oif age |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Zarif Jabbar-Lopez, MPH, MRCP | Contact | 020 7188 7188 | 57716 | zarif.jabbar-lopez@kcl.ac.uk |
| Name | Affiliation | Role |
|---|---|---|
| Carsten Flohr, PhD, FRCPCH | King's College London | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| St Thomas' Hospital | Recruiting | London | SE1 7EH | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34854157 | Derived | Jabbar-Lopez ZK, Ezzamouri B, Briley A, Greenblatt D, Gurung N, Chalmers JR, Thomas KS, Frost T, Kezic S, Common JEA, Danby S, Cork MJ, Peacock JL, Flohr C. Randomized controlled pilot trial with ion-exchange water softeners to prevent eczema (SOFTER trial). Clin Exp Allergy. 2022 Mar;52(3):405-415. doi: 10.1111/cea.14071. Epub 2021 Dec 12. | |
| 33006135 |
Not provided
Not provided
No plans to share IPD
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003876 | Dermatitis, Atopic |
| ID | Term |
|---|---|
| D012873 | Skin Diseases, Genetic |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D003872 | Dermatitis |
Not provided
Not provided
| OTHER |
| University of Amsterdam | OTHER |
| University of Dundee | OTHER |
Not provided
Not provided
Not provided
Not provided
|
| Proportion of families randomised that withdraw due to infant ineligibility | Baseline (birth) |
| Proportion of families in intervention arm who found the intervention acceptable | End of follow up (6 months of age) |
| Proportion of participants in control arm that become exposed to softened water | (e.g. by moving to a new home in a soft water area, or moving to a home with an active water softener installed, before the end of follow up) | End of follow up (6 months of age) |
| Proportion of participants that have the water softening unit removed or disabled prior to end of follow up | End of follow up (6 months of age) |
| Proportion of participants with visible eczema status (yes/no) recorded | According to UK diagnostic criteria-based photographic protocol | Baseline, 4 weeks, 3 and 6 months |
| Proportion of water samples with hardness >20 mg/L calcium carbonate | Would suggest failure of the water softening device | Between installation and end of follow up |
| Proportion of participants that withdraw from the trial prior to end of follow up | From randomisation until end of follow up |
| Median number of nights spent away from the participant's main home during follow up | From birth until end of follow up (6 months of age) |
| Proportion of clinical outcome assessments that have remained blinded | at 4 weeks, 3 & 6 months |
| Proportion with patient-reported, doctor-diagnosed eczema | by 6 months of age |
| Proportion with visible eczema according to the UK diagnostic criteria-based photographic protocol | 4 weeks, 3 & 6 months |
| Severity of eczema (if present) using Eczema Area and Severity Index (EASI) | 4 weeks, 3 & 6 months |
| Patient-reported eczema symptoms (Patient-Orientated Eczema Measure - POEM) | Monthly from 4 weeks to 6 months of age |
| Time to onset of patient-reported doctor-diagnosed eczema | from birth to end of follow up (6 months of age) |
| Natural moisturising factor (NMF) levels | at birth, 4 weeks, 3 & 6 months oif age |
| Shannon Diversity Index and other skin and respiratory microbiota parameters | at birth, 4 weeks, 3 & 6 months oif age |
| Proportion with filaggrin null mutations | at birth, 4 weeks, 3 & 6 months oif age |
| Effect of filaggrin (FLG) gene mutation status on TEWL, cytokine levels, NMF levels and skin microbiota diversity | at birth, 4 weeks, 3 & 6 months oif age |
| Median domestic water hardness level (calcium carbonate concentration) | at birth, 4 weeks, 3 & 6 months oif age |
| Skin hydration | at birth, 4 weeks, 3 & 6 months oif age |
| Laughter MR, Maymone MBC, Mashayekhi S, Arents BWM, Karimkhani C, Langan SM, Dellavalle RP, Flohr C. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017. Br J Dermatol. 2021 Feb;184(2):304-309. doi: 10.1111/bjd.19580. Epub 2020 Nov 29. |
| 31434765 | Derived | Jabbar-Lopez ZK, Gurung N, Greenblatt D, Briley A, Chalmers JR, Thomas KS, Frost T, Kezic S, Common JEA, Kong HH, Segre JA, Danby S, Cork MJ, Peacock JL, Flohr C. Protocol for an outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study: the Softened Water for Eczema Prevention (SOFTER) trial. BMJ Open. 2019 Aug 20;9(8):e027168. doi: 10.1136/bmjopen-2018-027168. |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D017443 | Skin Diseases, Eczematous |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |